TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M Nov. 12, 2024 9:48 AM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update